Tag: storage

Third Party Processing Growth and Strong Hedging Gain Bolsters Cash Flow, Drives Debt Reduction

CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its financial and operating results for the second quarter of 2025. The Company’s interim financial statements for the three and six months ended June 30, 2025 and related Management’s Discussion and Analysis (“MD&A”) are available on our website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca.

TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) --  (TSX: PWI, PWI.PR.A) Sustainable Power & Infrastructure Split Corp. (the “Fund”) is pleased to announce that the board of directors of the Fund has approved an extension of the maturity date of the class A shares (the “Class A Shares”) and preferred shares (the “Preferred Shares”) of the Fund. The current maturity date of May 29, 2026 will be extended for an additional term of approximately 5 years to May 29, 2031. The Preferred Share dividend rate for the extended term will be announced at least 60 days prior to the current May 29, 2026 maturity date and will be based on market yields for preferred shares with similar terms at that time. The term extension allows Class A shareholders to continue their investment with an attractive distribution rate of 10.2% based on the August 11, 2025 closing price, and the opportunity for capital appreciation.⁽¹⁾ The extension of the term of the Fund is not a taxable event and enables shareholders to defer potential capital gains tax liability that would have otherwise been realized on redemption of Class A Shares or Preferred Shares at the end of the term, until such time that shares are disposed of by shareholders.

CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) --  Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto" or the "Company") is pleased to report operating and financial results for the second quarter of 2025.

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026